The ASCO Post

The ASCO Post
CDK4/6 Inhibitors Combined With Fulvestrant for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: FDA Analysis of Overall Survival

Dr Jennifer Gao and colleagues found the addition of CDK4/6 inhibitor treatment to fulvestrant resulted in a consistent OS benefit vs placebo plus fulvestrant in patients with HR+.

The ASCO Post
Researchers Look at Access to Essential Cancer Drugs on a Global Scale

A recent study in The Lancet Oncology looked at whether the cancer therapeutics in the Essential Medicines List were aligned with the needs of oncologists worldwide.

The ASCO Post
Novel Therapies Under Study in Acute Myeloid Leukemia

Newly identified genetic abnormalities in AML, as well as therapies that can target some of those abnormalities, are now available as the landscape for treatment continues to evolve. 

The ASCO Post
Newer Agents on the Horizon for Refractory or Relapsed DLBCL

Some newer therapies are on the horizon for R/R DLBCL and offer promise, including bispecific antibodies, anti-CD47 antibodies, antibody-drug conjugates, and CAR T-cell therapy.

The ASCO Post
Addition of Ipatasertib to Abiraterone Plus Prednisolone Improves Radiographic Progression–Free Survival in Metastatic Castration-Resistant Prostate Cancer With PTEN Loss

A phase III trial found that the addition of the AKT inhibitor ipatasertib to abiraterone and prednisolone produced a significant improvement in radiographic progression-free survival... 

The ASCO Post
Friends of Cancer Research Releases White Paper on Optimizing Dosing in Oncology Drug Development

Friends urges stakeholders in the cancer community to work together to optimize dosing in oncology drug development to maximize benefit for patients and reduce treatment toxicity... 

The ASCO Post
FOCUS4-C Trial: Hint of Activity Reported With Adavosertib in Metastatic Colorectal Cancer

The novel WEE1 inhibitor adavosertib, given after induction chemotherapy, yielded a 65% reduction in the risk of disease progression or death compared with active monitoring in patients...

The ASCO Post
US Multisociety Task Force on Colorectal Cancer  Releases Updated Screening Recommendations

The US Multisociety Task Force on CRC has updated its CRC screening recommendations, specifically on when to start and when to stop screening in average-risk individuals.

The ASCO Post
Immunogenicity of SARS–CoV-2 Vaccines in Patients With Cancer

The CANVAX Cohort Study found that immunogenicity varied among vaccines and that both antibody concentrations and neutralization titers were lower than those in healthy controls. 

The ASCO Post
Long-Term Outcomes With Chemoradiotherapy Before vs After Chemotherapy in Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Long-term results of a German phase II trial showed similar disease outcomes, chronic toxicity, and QoL with chemoradiotherapy before vs after chemotherapy... 

The ASCO Post
Subscribe to The ASCO Post

source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rgb((217, 11, 193)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb (214, 104, 96)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)